What Motivates Patients to Join Clinical Trials: New Research Released by SCORR Marketing and Antidote Technologies
KEARNEY, Neb.--(BUSINESS WIRE)--Dec 5, 2018--SCORR Marketing, a global health science marketing and communications firm, in partnership with Antidote Technologies, a digital health company, has released an in-depth research report, The Patient Perspective on Clinical Trials. The detailed, 180-page report presents the findings from surveys conducted with patients about the motivations that lead them to participate in clinical trials.
The research includes comprehensive data gathered from selected partner organizations from Antidote’s Connect Network, including the American Kidney Fund, Allergy & Asthma Network, Healthline, JDRF, Lung Cancer Alliance, Lupus Research Alliance, Melanoma Research Alliance and Multiple Sclerosis Association of America. Almost 4,000 patients with a wide range of health concerns completed the survey.
“These are patients who, because of their health, generally know more about clinical research and are thus more likely to join a trial than the general population,” said Anne-Marie Hess, senior strategic advisor and market intelligence director at SCORR Marketing. “Understanding the attitudes of these patients is a strategic imperative if we expect to increase overall participation in clinical trials.”
Among other metrics, the report presents research about the patients who have participated in clinical studies and their reason for doing so, the extent of their knowledge about clinical trials, the motivations they would need to participate and the kinds of trials they are most interested in. The research provides data by condition, age, income, education, race, ethnicity and more.
“Arming biopharmaceutical and medical device organizations with this data can help them design clinical trial recruitment strategies with greater precision and enroll patients faster,” said Laurent Schockmel, CEO at Antidote Technologies. “Better clinical trial enrollment can help us advance and accelerate research for these conditions and ultimately improve the health of patients everywhere.”
Schockmel continued, “Together with SCORR Marketing, we would like to thank our partners for their important role in helping to advance medical research for all patients.”
The survey report is available for purchase here.
About SCORR Marketing SCORR Marketing is the leading full-service marketing and communications firm in the health science industry. We are a global partner for organizations around the world involved in research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we provide integrated programs that help our clients achieve their goals and improve health and well-being worldwide. For more information, visit www.scorrmarketing.com.
About Antidote Technologies Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients. For more information, please visit www.antidote.me.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181205005114/en/
CONTACT: Jane Byram
KEYWORD: UNITED STATES NORTH AMERICA NEBRASKA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL COMMUNICATIONS MARKETING RESEARCH SCIENCE
SOURCE: SCORR Marketing
Copyright Business Wire 2018.
PUB: 12/05/2018 08:00 AM/DISC: 12/05/2018 08:01 AM